The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.
Bernadette Anna Sophia Jaeger
No relevant relationships to disclose
Brigitte Kathrin Rack
Research Funding - Lilly; Novartis; Sanofi ; Veridex
Other Remuneration - Sanofi
Julia Katharina Neugebauer
No relevant relationships to disclose
Ulrich Andergassen
No relevant relationships to disclose
Carola Anna Melcher
No relevant relationships to disclose
Doraid Mouarrawy
No relevant relationships to disclose
Gabriele Ziemendorff
No relevant relationships to disclose
Michael Clemens
No relevant relationships to disclose
Ekkehard von Abel
No relevant relationships to disclose
Georg Heinrich
No relevant relationships to disclose
Katharina Schueller
No relevant relationships to disclose
Andreas Schneeweiss
No relevant relationships to disclose
Werner Lichtenegger
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Klaus Pantel
No relevant relationships to disclose
Harald Leo Sommer
Research Funding - Lilly; Novartis; Sanofi ; Veridex
Klaus Friese
No relevant relationships to disclose
Wolfgang Janni
Research Funding - Lilly; Novartis; Sanofi ; Veridex